Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Panitumumab + mFOLOFOX6 as the new standard of care for RAS WT metastatic colorectal cancer

Takayuki Yoshino, MD, PhD , National Cancer Center Hospital, Chiba, Japan, talks on the Phase III PARADIGM trial (NCT02394795), the results of which established a new standard of care (SOC) of panitumumab plus mFOLOFOX6 for patients with RAS wild-type metastatic colorectal cancer (mCRC). The PARADIGM study compared the anti-EGFR panitumumab versus the anti-VEGFR bevacizumab with mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC), demonstrating a higher overall-survival with panitumumab . This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.